Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Fineline Cube May 13, 2026
Company Deals

Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion

Fineline Cube May 13, 2026
Company Deals

Cellular Intelligence Acquires Global Rights to Novo Nordisk’s Parkinson’s Cell Therapy Program, Plans AI-Driven Acceleration

Fineline Cube May 13, 2026
Company Deals

Boehringer Ingelheim Secures Global Rights to Immunitas’ First-in-Class Antibody Program for Chronic Inflammatory Diseases in €407.5M Deal

Fineline Cube May 13, 2026
Company Deals

Mindray Bio-Medical Re-Files for Hong Kong Listing After Initial Application Expiration

Fineline Cube May 12, 2026
Policy / Regulatory

Hong Kong to Launch FDA-Style Medical Products Regulation Center by Year-End, Creating Gateway for Chinese Innovative Drugs

Fineline Cube May 13, 2026
Company Drug

Servier’s B7-H4 ADC Emiltatug Ledadotin Receives FDA Breakthrough Therapy Designation for Advanced Adenoid Cystic Carcinoma

Fineline Cube May 13, 2026
Company Drug

ImmuneOnco Receives NMPA Approval for IMM0306 Clinical Study in Primary Sjögren’s Syndrome, Expanding Dual-Target Bispecific Platform

Fineline Cube May 13, 2026
Company Deals

Aier Eye Hospital Group Plans IPO on ChiNext Board

Fineline Cube Oct 12, 2022

China-based ophthalmic medical services provider Aier Eye Hospital Group Co., Ltd (SHE: 300015) is set...

Company Deals

BeiGene Partners with Immune-Onc for Clinical Development of Myeloid Checkpoint Inhibitors

Fineline Cube Oct 12, 2022

China-based biotech BeiGene (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has entered into a clinical study...

Company Deals

Cyagen Biosciences Partners with Neurophth for Ophthalmology AAV Capsid Development

Fineline Cube Oct 12, 2022

Cyagen Biosciences, a provider of custom-engineered mouse and rat models with operations in the US...

Company Deals

IASO Biotherapeutics Licenses CD19 Binder to Cabaletta Bio for Autoimmune Diseases

Fineline Cube Oct 12, 2022

China-based IASO Biotherapeutics has announced a licensing agreement with US firm Cabaletta Bio Inc. (NASDAQ:...

Company Drug

Henlius Biotech’s HanBeiTai Biosimilar Accepted for Review by CDE

Fineline Cube Oct 12, 2022

Shanghai Henlius Biotech Inc. (HKG: 2696) has announced that a supplementary Biologic License Application (sBLA)...

Hospital Policy / Regulatory

Shanghai Launches High-Quality Development Pilot for Public Hospitals

Fineline Cube Oct 12, 2022

The Shanghai Municipal Health Commission (SHC) has released a notification regarding the public hospital high-quality...

Drug Policy / Regulatory

NMPA Introduces Electronic Certificates for Biologics and Narcotic Drugs

Fineline Cube Oct 12, 2022

The National Medical Products Administration (NMPA) has released a notification regarding the initiation of electronic...

Policy / Regulatory

CDE Releases Draft Guidelines for Tumor Therapeutic Vaccine Clinical Trials

Fineline Cube Oct 12, 2022

The Center for Drug Evaluation (CDE) has released the “Tumor Therapeutic Vaccines Clinical Trial Technical...

Company Deals

SprintRay Raises Over USD 100M in Series D Financing for Dental 3D Printing

Fineline Cube Oct 12, 2022

Zhejiang-based SprintRay Co., a one-stop digital chair side solution provider for dental institutions, has reportedly...

Company Drug

Pfizer’s Zavicefta Approved in China for Pediatric Complex Intra-Abdominal Infections

Fineline Cube Oct 11, 2022

US-based pharmaceutical giant Pfizer (NYSE: PFE) has announced that it has received market approval from...

Company Drug

HutchMed Initiates Phase II/III Study of Sovleplenib for Warm AIHA

Fineline Cube Oct 11, 2022

China-based Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) has announced the initiation of a...

Company Deals

Harbour BioMed Licenses Batoclimab to CSPC’s NBP Pharma for Greater China

Fineline Cube Oct 11, 2022

Harbour BioMed (HKG: 2142), a biotech company operating out of the United States, the Netherlands,...

Company Drug

Guangdong Zhongsheng Receives USPTO Patent for FGFR4 Inhibitor ZSP1241

Fineline Cube Oct 11, 2022

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced receiving a patent award from...

Company Drug

Simcere Completes Enrollment for Phase III Study of CDK4/6 Inhibitor in mTNBC

Fineline Cube Oct 11, 2022

China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the completion of first-line enrollment for its...

Company Drug

Hengrui Medicine’s Pyrotinib Filing Accepted for Review by NMPA

Fineline Cube Oct 11, 2022

China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced that its supplementary market filing...

Company Deals

China Resources Partners with Fosun Pharma to Expand Global Healthcare Footprint

Fineline Cube Oct 11, 2022

China Resources (Holdings) Co. Ltd (HKG: 3320) has entered into a strategic partnership with compatriot...

Company Drug

NMPA Approves JW Therapeutics’ Carteyva for Recurrent Follicular Lymphoma

Fineline Cube Oct 10, 2022

The National Medical Products Administration (NMPA) has granted another indication approval to China-based JW Therapeutics’...

Company Drug

Innovent’s Cyramza Gains NMPA Approval for Hepatocellular Carcinoma

Fineline Cube Oct 10, 2022

Innovent Biologics Inc. (HKG: 1801) has announced that the supplementary Biologic License Application (sBLA) for...

Company Drug

Sciwind Biosciences Initiates US Phase I Study for GLP-1 Agonist XW014

Fineline Cube Oct 10, 2022

China-based Sciwind Biosciences Co., Ltd has announced the initiation and first patient dosing of a...

Company Deals

Fujian Cosunter to Acquire UDCA Capsules Technology from Ruitailai

Fineline Cube Oct 10, 2022

China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced plans to enter into a...

Posts pagination

1 … 615 616 617 … 665

Recent updates

  • Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms
  • Sichuan Kelun-Biotech Receives NMPA Approval for ITGB6-Targeted ADC SKB105 in Advanced Solid Tumors Following Crescent Biopharma Licensing Deal
  • Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion
  • Cellular Intelligence Acquires Global Rights to Novo Nordisk’s Parkinson’s Cell Therapy Program, Plans AI-Driven Acceleration
  • Porton Advanced Solutions and Dark Horse Consulting Forge Strategic Alliance to Accelerate Global Cell and Gene Therapy Development
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Others

Sichuan Kelun-Biotech Receives NMPA Approval for ITGB6-Targeted ADC SKB105 in Advanced Solid Tumors Following Crescent Biopharma Licensing Deal

Company Deals

Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion

Company Deals

Cellular Intelligence Acquires Global Rights to Novo Nordisk’s Parkinson’s Cell Therapy Program, Plans AI-Driven Acceleration

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.